Heart failure (HF) has been recognized as a common complication of diabetes, with a
prevalence of up to 22% in individuals with diabetes and increasing incidence rates. Data …

Chronic kidney disease (CKD) as identified by a reduced estimated glomerular filtration rate
(eGFR) is a common comorbidity in patients with heart failure with reduced ejection fraction …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Background The use of guideline-directed medical therapy (GDMT) is underprescribed in
patients with heart failure with reduced ejection fraction (HFrEF). Objectives This study …

Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a
foundational therapy for patients with heart failure (HF) and reduced ejection fraction …

Aims Use and dosing of guideline‐directed medical therapy (GDMT) in patients with heart
failure (HF) have been shown to be suboptimal. Among new users of GDMT in HF, we …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …

Aims Previously, guidelines recommended initiating therapy in patients with heart failure
and reduced ejection fraction (HFrEF) in a sequence that follows the chronological order in …

Heart failure (HF) continues to be a major contributor of morbidity and mortality for men and
women alike, yet how the predisposition for, course and management of HF differ between …